KYAN Technologies will present at the 15th Biennial Ovarian Cancer Research Symposium, hosted by The Rivkin Center for Ovarian Cancer and the American Association for Cancer Research (AACR). The symposium was scheduled to take place in Seattle, USA, on September 20-21, 2024.
Presenter and KYAN’s Chief Scientific Officer, Dr. Edward Chow, Ph.D., commented, “This study provides early evidence that Optim.AI™ can be successfully performed on cryopreserved ovarian cancer samples to predict treatment response to platinum-based treatments as well as other combination-based alternatives. Even more exciting is paired analysis comparing cancer cells from the primary tumor compared to ascites fluid revealed matching Optim.AI™ results, suggesting that Optim.AI™ may work with less invasive biopsy samples.”
KYAN has successfully performed its Optim.AI™ test across more than 14 solid cancer types. The study with University of Basel has further enhanced KYAN’s growing experience and data generation.